Update on CheckMate 067, an advanced melanoma clinical trial - European Medical Journal

Update on CheckMate 067, an advanced melanoma clinical trial

Oncology

James Larkin, MD, PhD gives an update on the clinical trial CheckMate 067, a phase 3 study of Nivolumab or Nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma.

This updated was presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now